Cencora, Inc. $COR Shares Sold by Atria Investments Inc

Atria Investments Inc lowered its stake in Cencora, Inc. (NYSE:COR) by 10.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 43,779 shares of the company’s stock after selling 4,982 shares during the quarter. Atria Investments Inc’s holdings in Cencora were worth $14,786,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Marshall Wace LLP raised its position in shares of Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after acquiring an additional 1,672,762 shares in the last quarter. Mizuho Markets Americas LLC raised its position in shares of Cencora by 116.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after acquiring an additional 1,511,906 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after acquiring an additional 1,241,186 shares in the last quarter. Viking Global Investors LP raised its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after acquiring an additional 1,013,913 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Cencora by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after acquiring an additional 916,506 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Down 2.0%

NYSE:COR opened at $255.59 on Thursday. The firm has a market cap of $49.72 billion, a P/E ratio of 19.60, a PEG ratio of 1.20 and a beta of 0.64. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The stock’s 50 day simple moving average is $319.08 and its 200-day simple moving average is $340.30. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the previous year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts anticipate that Cencora, Inc. will post 17.76 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s payout ratio is presently 18.40%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. William Blair assumed coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating on the stock. JPMorgan Chase & Co. raised their target price on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Weiss Ratings reissued a “buy (b)” rating on shares of Cencora in a research report on Monday, May 4th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Finally, Morgan Stanley set a $342.00 price target on Cencora in a research note on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.